People Who Drink and Occasionally Use Psilocybin Score Lower on Depression Scales. Don't Call It a Treatment Yet.

Here’s a finding that will get mangled by a headline somewhere before the week is out, so let’s say the careful version first: people who drink alcohol and also use psilocybin mushrooms occasionally scored noticeably lower on a standard depression questionnaire than people who only drink — but people who used psilocybin frequently didn’t show the same pattern. The dose that seemed to track with better mental health was the smallest one.

A finding this specific deserves better than either “magic mushrooms cure depression” or “ignore it” — it deserves you reading the actual caveat the researchers put on it themselves.

The study, published in the Journal of Drug Issues and led by Anita Cservenka, who directs the Substance Use and Neurocognition Lab at Oregon State University, surveyed 2,841 people — 1,234 who used both alcohol and psilocybin, 1,607 who used alcohol only — drawn from the 2024 National Survey Investigating Hallucinogenic Trends. Co-users scored about half a point lower on the PHQ-9, a standard 27-point depression scale, than alcohol-only drinkers in models adjusted for other factors; unadjusted comparisons showed a full point of difference on depression and two-thirds of a point on an anxiety measure, PsyPost reported August 1. Cservenka herself frames the value of the data as its ordinariness: it captures “more real-world, naturalistic use” than the tightly controlled, high-dose, clinically supervised sessions that make headlines in psilocybin-therapy trials.

That framing matters because it’s also the study’s limit. This is a cross-sectional survey — a single snapshot, not a trial that tracked anyone over time — so it cannot tell you whether psilocybin use lowered people’s depression, or whether people who already felt better were simply more inclined to try psilocybin in the first place, or whether some third factor (income, social support, what else they were using) explains both. There’s no substance-naive comparison group either, so “psilocybin users vs. alcohol-only users” isn’t the same question as “psilocybin vs. nothing.” None of that makes the finding meaningless. It makes it a genuine data point about how people are actually using this drug outside a lab, at a moment when investment and FDA attention are both pouring into psilocybin as a clinical treatment — worth knowing, worth researching further, not worth prescribing to yourself based on a single survey.

If you’re in recovery and alcohol is part of your history, the honest takeaway isn’t “try mushrooms.” It’s that the people studying this seriously are being careful not to oversell it — and that’s a standard worth holding every psychedelics headline to, including the next one.